BR112022025586A2 - Liberação de vetor de vírus adenoassociado para distrofias musculares - Google Patents
Liberação de vetor de vírus adenoassociado para distrofias muscularesInfo
- Publication number
- BR112022025586A2 BR112022025586A2 BR112022025586A BR112022025586A BR112022025586A2 BR 112022025586 A2 BR112022025586 A2 BR 112022025586A2 BR 112022025586 A BR112022025586 A BR 112022025586A BR 112022025586 A BR112022025586 A BR 112022025586A BR 112022025586 A2 BR112022025586 A2 BR 112022025586A2
- Authority
- BR
- Brazil
- Prior art keywords
- adeno
- associated virus
- muscular dystrophies
- virus vector
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
LIBERAÇÃO DE VETOR DE VÍRUS ADENOASSOCIADO PARA DISTROFIAS MUSCULARES. A presente invenção refere-se a um método de tratamento de distrofia muscular em um indivíduo em necessidade, compreendendo a administração de um vetor de terapia gênica, tal como vetor do vírus adenoassociado (AAV), expressando um gene de microdistrofina humana miniaturizada em combinação com uma etapa de supressão do sistema imunológico do indivíduo.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063039252P | 2020-06-15 | 2020-06-15 | |
US202063083953P | 2020-09-27 | 2020-09-27 | |
US202163160376P | 2021-03-12 | 2021-03-12 | |
US202163188266P | 2021-05-13 | 2021-05-13 | |
PCT/US2021/037470 WO2021257595A1 (en) | 2020-06-15 | 2021-06-15 | Adeno-associated virus vector delivery for muscular dystrophies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022025586A2 true BR112022025586A2 (pt) | 2023-03-07 |
Family
ID=77051123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022025586A BR112022025586A2 (pt) | 2020-06-15 | 2021-06-15 | Liberação de vetor de vírus adenoassociado para distrofias musculares |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210393801A1 (pt) |
EP (1) | EP4164668A1 (pt) |
JP (1) | JP2023530974A (pt) |
KR (1) | KR20230035043A (pt) |
CN (1) | CN116348149A (pt) |
AU (1) | AU2021293197A1 (pt) |
BR (1) | BR112022025586A2 (pt) |
CA (1) | CA3187353A1 (pt) |
CO (1) | CO2023000156A2 (pt) |
IL (1) | IL299094A (pt) |
MX (1) | MX2022016332A (pt) |
TW (1) | TW202208630A (pt) |
WO (1) | WO2021257595A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109121395B (zh) * | 2016-04-15 | 2022-08-09 | 全国儿童医院研究所 | 腺相关病毒载体递送β-肌聚糖和微RNA-29以及肌营养不良症的治疗 |
WO2024006855A1 (en) * | 2022-06-30 | 2024-01-04 | Sarepta Therapeutics, Inc. | Methods of treating muscular dystrophy |
WO2024138158A2 (en) | 2022-12-23 | 2024-06-27 | Ultragenyx Pharmaceutical Inc. | Method of producing soluble microdystrophin protein and uses of the same |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
PT733103E (pt) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | Criacao de elevados titulos de vectores de aav recombinantes |
JP3952312B2 (ja) | 1993-11-09 | 2007-08-01 | メディカル カレッジ オブ オハイオ | アデノ関連ウイルス複製遺伝子を発現可能な安定な細胞株 |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
US6143548A (en) | 1995-08-30 | 2000-11-07 | Genzyme Corporation | Chromatographic purification of adeno-associated virus (AAV) |
ES2317646T3 (es) | 1995-09-08 | 2009-04-16 | Genzyme Corporation | Vectores aav mejorados para terapia genica. |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
ATE465267T1 (de) | 1996-09-06 | 2010-05-15 | Univ Pennsylvania | Rekombinante aav zur herstellung eines medikaments für die gentherapie von muskelzellen |
US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
PT1944362E (pt) | 1997-09-05 | 2016-01-27 | Genzyme Corp | Métodos de produção de preparações de alto título de vetores aav recombinantes desprovidos de adjuvantes |
US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
CA2319468A1 (en) | 1998-02-03 | 1999-08-12 | Inex Pharmaceuticals Corporation | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6211140B1 (en) | 1999-07-26 | 2001-04-03 | The Procter & Gamble Company | Cationic charge boosting systems |
AU2001255575B2 (en) | 2000-04-28 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
AU2002248297A1 (en) | 2001-01-05 | 2002-07-16 | Children's Hospital, Inc. | Aav2 vectors and methods |
PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
CA2491164C (en) | 2002-06-28 | 2012-05-08 | Cory Giesbrecht | Method and apparatus for producing liposomes |
JP4951338B2 (ja) | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質に封入された干渉rna |
US6927663B2 (en) | 2003-07-23 | 2005-08-09 | Cardiac Pacemakers, Inc. | Flyback transformer wire attach method to printed circuit board |
WO2005026372A1 (en) | 2003-09-15 | 2005-03-24 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
JP4764426B2 (ja) | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
EP1937213B1 (en) | 2005-07-27 | 2017-10-25 | Protiva Biotherapeutics Inc. | Systems and methods for manufacturing liposomes |
US9149564B2 (en) | 2006-06-23 | 2015-10-06 | The Regents Of The University Of California | Articles comprising large-surface-area bio-compatible materials and methods for making and using them |
EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
EP3808177A1 (en) | 2008-11-10 | 2021-04-21 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
JP5766188B2 (ja) | 2009-07-01 | 2015-08-19 | プロチバ バイオセラピューティクス インコーポレイティッド | 固形腫瘍に治療剤を送達するための脂質製剤 |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
WO2011004395A1 (en) | 2009-07-06 | 2011-01-13 | Intas Biopharmaceuticals Limited | Microemulsion formulation for biologicals |
US20130022649A1 (en) | 2009-12-01 | 2013-01-24 | Protiva Biotherapeutics, Inc. | Snalp formulations containing antioxidants |
CA2783372C (en) | 2009-12-07 | 2019-07-16 | Muthiah Manoharan | Compositions for nucleic acid delivery |
AU2010330814B2 (en) | 2009-12-18 | 2017-01-12 | Acuitas Therapeutics Inc. | Methods and compositions for delivery of nucleic acids |
CN103002891B (zh) | 2010-05-10 | 2016-10-26 | 加利福尼亚大学董事会 | 比例计量型组合药物递送 |
EP2569276B1 (en) | 2010-05-12 | 2021-02-24 | Arbutus Biopharma Corporation | Novel cationic lipids and methods of use thereof |
KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
EP3202760B1 (en) | 2011-01-11 | 2019-08-21 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
WO2013016126A1 (en) | 2011-07-22 | 2013-01-31 | The General Hospital Corporation | Therapeutic nanoparticles and methods of use thereof |
CA3106285A1 (en) | 2011-07-25 | 2013-01-31 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
CA2849476A1 (en) | 2011-09-27 | 2013-04-04 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
US8762704B2 (en) | 2011-09-29 | 2014-06-24 | Apple Inc. | Customized content for electronic devices |
EP2788316B1 (en) | 2011-12-07 | 2019-04-24 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
WO2013086354A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
WO2014008334A1 (en) | 2012-07-06 | 2014-01-09 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
KR101890951B1 (ko) | 2012-12-20 | 2018-08-22 | 에스케이이노베이션 주식회사 | 합성 가스 및 고품위 석탄의 동시 생산을 위한 건조 및 가스화 통합 공정 |
JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
JP6202701B2 (ja) | 2014-03-21 | 2017-09-27 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及びプログラム |
PL3766916T3 (pl) | 2014-06-25 | 2023-02-27 | Acuitas Therapeutics Inc. | Nowe lipidy i formulacje nanocząstek lipidowych do dostarczania kwasów nukleinowych |
JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
NZ734019A (en) | 2015-01-16 | 2023-01-27 | Univ Washington | Novel micro-dystrophins and related methods of use |
PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
WO2017075531A1 (en) | 2015-10-28 | 2017-05-04 | Acuitas Therapeutics, Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
TN2018000163A1 (en) | 2015-11-12 | 2019-10-04 | Res Inst Nationwide Childrens Hospital | Methods of treating muscular dystrophy |
WO2017117528A1 (en) | 2015-12-30 | 2017-07-06 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
MA45477A (fr) * | 2016-04-15 | 2019-02-20 | Res Inst Nationwide Childrens Hospital | Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire |
CA2971303A1 (en) | 2016-06-21 | 2017-12-21 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
CN107369008A (zh) | 2017-07-17 | 2017-11-21 | 北京京东金融科技控股有限公司 | 用于提高票据交易安全性的管理方法、装置及系统 |
EP3697915A4 (en) * | 2017-10-18 | 2021-12-08 | Research Institute at Nationwide Children's Hospital | ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE SPECIFIC MICRODYSTROPHIN FOR THE TREATMENT OF MUSCLE DYSTROPHY |
WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
WO2019118806A1 (en) | 2017-12-14 | 2019-06-20 | Solid Biosciences Inc. | Non-viral production and delivery of genes |
CN111818946A (zh) * | 2018-01-31 | 2020-10-23 | 国家儿童医院研究所 | 2c型肢带型肌营养不良的基因疗法 |
WO2019177550A1 (en) | 2018-03-10 | 2019-09-19 | Koc Universitesi | Therapeutic nanoparticles containing argonaute for microrna delivery and compositions and methods using same |
CN111971050A (zh) | 2018-04-03 | 2020-11-20 | 密苏里大学管理机构 | 用于抗肌萎缩蛋白病治疗的铰链1和/或4修饰的抗肌萎缩蛋白 |
WO2019209777A1 (en) | 2018-04-23 | 2019-10-31 | The Curators Of The University Of Missouri | Improved crispr therapy |
JP2021527657A (ja) * | 2018-06-18 | 2021-10-14 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクターデリバリー |
KR20210028162A (ko) | 2018-06-29 | 2021-03-11 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 지대근 이영양증 2a형을 치료하기 위한 재조합 아데노 연관 바이러스 생성물 및 방법 |
JP7543259B2 (ja) | 2018-10-18 | 2024-09-02 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
AU2019395388A1 (en) | 2018-12-12 | 2021-07-29 | Solid Biosciences Inc. | Combination therapy for treating muscular dystrophy |
MX2021010356A (es) | 2019-02-26 | 2022-03-04 | Res Inst Nationwide Childrens Hospital | SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR. |
-
2021
- 2021-06-15 WO PCT/US2021/037470 patent/WO2021257595A1/en active Application Filing
- 2021-06-15 CA CA3187353A patent/CA3187353A1/en active Pending
- 2021-06-15 TW TW110121662A patent/TW202208630A/zh unknown
- 2021-06-15 US US17/348,515 patent/US20210393801A1/en active Pending
- 2021-06-15 IL IL299094A patent/IL299094A/en unknown
- 2021-06-15 JP JP2022577296A patent/JP2023530974A/ja active Pending
- 2021-06-15 MX MX2022016332A patent/MX2022016332A/es unknown
- 2021-06-15 BR BR112022025586A patent/BR112022025586A2/pt unknown
- 2021-06-15 CN CN202180055748.XA patent/CN116348149A/zh active Pending
- 2021-06-15 EP EP21746204.3A patent/EP4164668A1/en active Pending
- 2021-06-15 AU AU2021293197A patent/AU2021293197A1/en active Pending
- 2021-06-15 KR KR1020237001636A patent/KR20230035043A/ko active Search and Examination
-
2023
- 2023-01-10 CO CONC2023/0000156A patent/CO2023000156A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230035043A (ko) | 2023-03-10 |
CO2023000156A2 (es) | 2023-03-27 |
JP2023530974A (ja) | 2023-07-20 |
US20210393801A1 (en) | 2021-12-23 |
MX2022016332A (es) | 2023-04-03 |
EP4164668A1 (en) | 2023-04-19 |
IL299094A (en) | 2023-02-01 |
CA3187353A1 (en) | 2021-12-23 |
WO2021257595A1 (en) | 2021-12-23 |
AU2021293197A1 (en) | 2023-02-09 |
CN116348149A (zh) | 2023-06-27 |
TW202208630A (zh) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022025586A2 (pt) | Liberação de vetor de vírus adenoassociado para distrofias musculares | |
AR111292A1 (es) | Administración de vectores del virus adenoasociado de microdistrofina específica del músculo para tratar la distrofia muscular | |
BR112018071167A2 (pt) | entrega de beta-sarcoglicano e microrna-29 por vírus adenoassociado e tratamento de distrofia muscular | |
BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
BR112018011975A2 (pt) | composições úteis no tratamento de atrofia muscular espinhal | |
BR112016028023A2 (pt) | Composições e métodos de administração de tratamentos para infecções virais latentes | |
BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
MX2021006094A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
BR112018076124A2 (pt) | tratamento de amd utilizando a variante de aav2 com aflibercept | |
BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
BR112015018255A2 (pt) | Usos de vetores que compreendem sequência de ácido nucléico de um gene para a preparação de medicamentos para o tratamento e a prevenção de cardiomiopatia | |
BR112016022854A2 (pt) | método para tratar, aliviar ou proteger (prevenir), diminuir o progresso ou reverter uma doença, método para tratar, aliviar ou proteger (prevenir) uma doença, uso, e, ácido nucleico ou gene | |
CO2021000227A2 (es) | Suministro mediante vectores de virus adenoasociado de microdistrofina específica del músculo para tratar la distrofia muscular | |
WO2020123645A8 (en) | Combination therapy for treating muscular dystrophy | |
BR112015021470A2 (pt) | conjugado de polímero para administração de um agente bioativo | |
CL2021002881A1 (es) | Composiciones útiles en el tratamiento de leucodistrofia metacromática | |
JP2015529685A5 (pt) | ||
BR112018075300A2 (pt) | métodos para tratamento do mal de alzheimer | |
BR112022006530A2 (pt) | Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c | |
CO2021012074A2 (es) | Suministro de β-sarcoglicano mediante vectores de virus adenoasociado y el tratamiento de la distrofia muscular | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
MX2016014346A (es) | Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada. | |
BR112016007390A8 (pt) | Vacina de haemophilus parasuis sorotipo tipo quatro | |
BR112023004020A2 (pt) | Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r |